| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Platinum-based adjuvant chemotherapy after complement resection has become a standard treatment for patients with stage II and IIIA non-small cell lung cancer. However, not all patients exhibited survival benefits. Therefore, the development of predictive biomarkers for selecting a subgroup of patients who may show improved survival after those treatment is important. In this project, I explored novel predictive biomarkers of the effect of platinum-based adjuvant chemotherapy via several kinds of proteomics techniques. Then, I validated their utility for predicting the prognosis of the patients with completely resected non-small cell lung cancer receiving platinum-based adjuvant chemotherapy. I reported that S100A16, nestin, TRAP1 and galectin-3 were promising candidate as prognostic biomarkers for these patients.
|
